IL17A and inflammatory bowel disease: Nonetheless, clinical trials have demonstrated that secukinumab, an IL-17A inhibitor that is effective in treating psoriasis and PsA, is associated with the onset or exacerbation of IBD, including Crohn’s disease and ulcerative colitis.